Page 2 - Secondary Progressive Multiple Sclerosis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Secondary progressive multiple sclerosis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Secondary Progressive Multiple Sclerosis Today - Breaking & Trending Today

Phase 2 Clinical Trial For SPMS With Intranasal Monoclonal Antibody

Tiziana Life Sciences expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis that’s administered through the nose. ....

Tiziana Life Sciences , Secondary Progressive Multiple Sclerosis , Emission Tomography , Modified Fatigue Impact Scale , Expanded Disability Status Scale , Foot Walk Test , Neuroqol Fatigue ,

Tiziana Life Sciences : Updated Interim Results for the Six Months Ended 30 June 2023 - Form 6-K -December 29, 2023 at 04:39 pm EST

Updated Interim Results for the Six Months Ended 30 June 2023

NEW YORK, December 29, 2023 - Tiziana Life Sciences, Ltd. , a biotechnology company developing breakthrough. ....

United States , United Kingdom , City Of , Tanuja Chitnis , Matthew Davis , Monte Carlo , Gabriele Cerrone , Saef Izzy , Williama Haseltine , Williama Clementi , Paul Spencer , Irina Koffler , Howard Weiner , Tiziana Life Sciences , Lifesci Advisors , Pharma Ltd , International Accounting Standards Board , International Conference On Alzheimer , Tiziana Life Sciences Ltda Bermudan , Investment In Related Party , Proceedings Of The National Academy Sciences , Tiziana Life Sciences Ltd , Ann Romney Center , American Academy Of Neurology , Investment In Accustem Sciences Inc , Clinical Program Updates ,

Tiziana Life Sciences : Interim Results for the Six Months Ended 30 June 2023 863.7 KB -December 29, 2023 at 04:39 pm EST

Tiziana Life Sciences Ltd

Updated Interim Results for the Six Months Ended 30 June 2023

NEW YORK, December 29, 2023 -. ....

United States , Gabriele Cerrone , Tanuja Chitnis , Matthew Davis , Irina Koffler , Howard Weiner , Saef Izzy , Williama Haseltine , Paul Spencer , Williama Clementi , Tiziana Life Sciences , Lifesci Advisors , International Conference On Alzheimer , Investment In Related Party , Tiziana Life Sciences Ltd , Business Development , Proceedings Of The National Academy Sciences , American Academy Of Neurology , Research In Multiple Sclerosis , Ann Romney Center , Clinical Program Updates , Drug Administration , European Committee For Treatment , Interim Results , Six Months Ended , Life Sciences ,

Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal…

This month, Tiziana Life Sciences TLSA expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary… ....

Tiziana Life Sciences , Secondary Progressive Multiple Sclerosis , Have Few Effective , Reaking News ,

Tiziana Expects To Start Enrolling Patients in Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using its Novel Intranasal Monoclonal Antibody Foralumab - Tiziana Life Sciences (NASDAQ:TLSA)

This month, Tiziana Life Sciences (NASDAQ: TLSA) expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s administered through the nose. ....

Tanuja Chitnis , Gabriele Cerrone , Professor Of Neurology At Harvard Medical School , Tiziana Life , Secondary Progressive Multiple Sclerosis , Have Few Effective Treatment Options , Have Even Fewer , Difference In Patient , Emission Tomography , Modified Fatigue Impact Scale , Principal Investigator , Harvard Medical School , Expanded Disability Status Scale , Foot Walk Test , Neuroqol Fatigue , Tiziana Founder Gabriele ,